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Association of Gestational Opioid Exposure and Risk of Major
and Minor Congenital Malformations
Xuerong Wen, PhD, MPH; Nicholas Belviso, PhD, PharmD; Emily Murray, PharmD; Adam K. Lewkowitz, MD, MPHS;
Kristina E. Ward, PharmD; Kimford J. Meador, MD

Abstract
IMPORTANCE The rapid increase of opioid-related overdoses and deaths has become a public
health concern in the US. Use of prescription opioids in pregnant women has increased; results from
teratogenicity studies remain controversial.

Key Points
Question Is there an association
between prenatal prescription opioid
exposure and the risk of major and
minor congenital malformations?

OBJECTIVE To evaluate the association between maternal prescription opioid use (excluding opioid

Findings In this cohort study of 12 424

use disorders) during pregnancy and the incidence of congenital malformations.

pregnancies, 891 women were
dispensed prescription opioids during

DESIGN, SETTING, AND PARTICIPANTS This retrospective population-based cohort study

pregnancy. Opioid exposure in trimester

evaluated linked Rhode Island Medicaid claims and vital statistics data of live births from January 1,

1 was not associated with major birth

2008, to December 31, 2016. Data analysis was conducted from May 1, 2019, to May 31, 2020.

defects, but women dispensed opioids

Women who had a live birth during the study period, but no cancer or opioid use disorder, were

in trimester 3 had higher risks of

followed up from 3 months before pregnancy to the end of pregnancy.

offspring with minor birth defects in the
musculoskeletal system.

EXPOSURES Data on the mother’s prescription opioid exposure were obtained through pharmacy
claims and exposure was defined as dispensing of at least 1 prescription opioid during the first,
second, or third trimester.

Meaning The study findings suggest a
higher risk of minor congenital
malformations in the musculoskeletal
system that is associated with prenatal

MAIN OUTCOMES AND MEASURES The primary outcome was overall major or minor congenital
malformations, defined as 1 or more major or minor congenital malformation. Secondary outcomes
were defined as 10 specific categories of congenital malformations classified by organ systems using

prescription opioid exposure in the third
trimester; this risk appears to be
dose-dependent.

International Classification of Diseases diagnosis codes.
RESULTS Of 12 424 included pregnancies, 891 mothers (7.2%) received prescription opioids during
pregnancy and 3153 infants (25.4%) were diagnosed with major or minor congenital malformations.
Comparing prescription opioid exposure vs nonexposure, no excess risk was observed for major birth

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

defects in infants with opioid exposure in trimester 1 (adjusted relative risk [aRR], 1.40; 95% CI,
0.84-2.34), and higher risks were found for overall minor birth defects in trimester 3 (aRR, 1.26; 95%
CI, 1.04-1.53) and minor birth defects in the musculoskeletal system in trimester 2 (aRR, 1.50; 95%
CI, 1.10-2.03) and trimester 3 (aRR, 1.65; 95% CI, 1.23-2.22). Significant dose responses in selected
minor malformations and effects of specific opioids were also identified. Hydrocodone in trimester 2
(aRR, 3.01; 95% CI, 1.80-5.03) and oxycodone in trimester 3 (aRR, 2.43; 95% CI, 1.37-4.02) were
associated with plagiocephaly, polydactyly, and other specified congenital deformities of the hip.
CONCLUSIONS AND RELEVANCE The findings of this study suggest a higher risk of minor
congenital malformations associated with use of prenatal prescription opioids in trimester 3, which
seems to be dose-dependent. Further investigation is needed to establish causality and explore the
physiologic plausibility of the association.
JAMA Network Open. 2021;4(4):e215708. doi:10.1001/jamanetworkopen.2021.5708
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Introduction
Pharmacologic analgesia plays a role in pain treatment during pregnancy.1,2 The American College of
Obstetricians and Gynecologists recommends that alternative pain management strategies should
be prioritized to avoid or minimize opioid exposure during gestation.3 However, common opioid use
continues, presumedly because the benefits of treatment are considered to outweigh the risks of
harm to both mother and infant.4,5
Studies are limited, and results are controversial regarding the effects of prenatal prescription
opioid exposure on the risk of congenital malformations. Two recent large cohort studies reported
that prenatal opioid exposure in the first trimester is not associated with a higher risk of major
congenital malformations,6,7 but codeine use during early pregnancy was associated with a higher
risk of spina bifida.7 Other studies suggested that gestational opioid exposure is associated with the
risk of congenital malformations.8-10 Thus, whether opioid use in pregnancy is associated with major
congenital malformations remains unclear. The goal of this study was to evaluate the risk of
congenital malformations associated with gestational prescription opioid exposure among pregnant
women enrolled in the Rhode Island state Medicaid program.

Methods
Data Sources
This retrospective cohort study was conducted with linked Rhode Island Medicaid claims and vital
statistics data provided by the Rhode Island Department of Health and Rhode Island Executive Office
of Health & Human Services. Details about the data linkage and data fields are described elsewhere.11
This study was designated exempt and informed consent was waived by the institutional review
boards at the Rhode Island Department of Health and the University of Rhode Island because the
study data were deidentified. This study followed the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) reporting guideline for cohort studies.

Study Design and Cohort
We included mothers enrolled in Rhode Island Medicaid who had a live birth occurring between
January 1, 2008, and December 31, 2016. Data analysis was conducted from May 1, 2019, to May 31,
2020. Eligible mothers were required to have continuous Rhode Island state Medicaid coverage from
3 months before the estimated conception date and throughout the pregnancy. Women were
excluded if they had a cancer diagnosis or chromosomal abnormalities (International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 758, 759.81, 759.82, and 759.83),
had an opioid use disorder diagnosis, or received any medication-assisted treatments for opioid use
disorder from 3 months before the conception date to the end of the pregnancy to avoid
confounding from opioid use disorders. We excluded women exposed to the following teratogenic
agents at any time during the baseline and pregnancy periods: isotretinoin, bexarotene, etretinate,
phenobarbital, valproate, lithium, tazarotene, warfarin, misoprostol, mycophenolate, and
thalidomide. To avoid exposure misclassification, we further excluded women dispensed
prescription opioids during the 3-month baseline window, but not during the pregnancy.

Assessment of Exposure
Prescription opioid exposure data were obtained through outpatient pharmacy claims reported by
Rhode Island Medicaid using National Drug Codes, therapeutic class codes, or drug names. To
separate outcomes of opioid use from major and minor congenital malformations, exposure was
defined based on the etiologically relevant exposure window. Exposure was defined as having at
least 1 day’s supply of a prescription opioid anytime during pregnancy trimesters 1, 2, or 3. Gestational
age was derived through ultrasonographic examination of mothers and was a component of the
Rhode Island Department of Health birth certificate data. Conception date was estimated by
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subtracting the infant’s gestational age, derived by ultrasonographic examination, from the infant’s
date of birth. The first 3 months before the conception date were evaluated for baseline
characteristics and use of medication. The pregnancy window included the period from the
conception date through the delivery date. Trimester 1 was defined as from the conception date
through 90 days after the conception date, trimester 2 was from 91 to 180 days after the conception
date, and trimester 3 was from 181 days after the conception date to the delivery date. The
comparison group included all mothers who had no prescription opioids dispensed during the
baseline and pregnancy window.

Outcome Definition
In this study, we assessed major and minor congenital malformations separately. Major congenital
malformations included 47 birth defects that were defined by surveillance guidelines developed by
the National Birth Defects Prevention Network.12 Cases of major congenital malformations were
reported by Rhode Island birthing hospitals and ascertained by the Rhode Island Birth Defects
Program through medical records review.13 All minor congenital malformations were identified using
ICD-9-CM or International Statistical Classification of Diseases, Tenth Revision, Clinical Modification
(ICD-10-CM) diagnosis codes from the infant’s Medicaid claims (eTable 1 in the Supplement) after
excluding all major congenital malformations.14,15 Primary study outcomes included overall major or
minor congenital malformations, defined as 1 or more major or minor congenital malformations.
Secondary outcomes were defined as 10 specific categories of major or minor congenital
malformations classified by organ system (eTable 1 in the Supplement).16-19 Classification was based
on the ICD-10-CM codes and corresponding ICD-9-CM codes developed by the World Health
Organization and adapted by the Centers for Disease Control and Prevention.15,20 This classification
of birth defects has been implemented in many state birth defects monitoring systems and applied
and validated in drug teratogenicity studies.21-25
Potential demographic and clinical risk factors were assessed 3 months before the conception
date and controlled for in the analyses. Covariates taken into consideration were classified into
several categories, including maternal demographic characteristics, substance use disorders, pain
conditions, medical history, and concomitant drug use during baseline and the pregnancy
window.26,27 Most covariates (eg, maternal tobacco use, alcohol consumption, other substance use,
comorbidities, and comedication use) were identified using ICD-9-CM or ICD-10-CM codes, National
Drug Codes, therapeutic class codes, or drug names from the Medicaid claims. Maternal age, year of
delivery, and multiple births were extracted from the Rhode Island vital statistics data.

Statistical Analysis
Descriptive analyses of baseline demographic and clinical variables were conducted. Continuous
variables are presented as mean (SD) and compared using a 2-tailed, unpaired t test. Categorical
variables are presented as frequency and percentage and compared using a χ2 or Fisher exact test.
A propensity score, fine-stratification approach with 50 strata was adopted to adjust for
multiple confounding factors.28,29 Multivariable logistic regression analyses with propensity score
fine-stratification weighting were applied to obtain the final estimates and corresponding 95% CIs.
Adjusted relative risk (aRR) values were obtained using the log link function and binomial
distribution.
Numerous prespecified sensitivity analyses were performed. First, dose-response relationships
were examined for opioids dispensed with different cumulative opioid doses. A cumulative opioid
dose for each exposed mother was calculated using morphine milligram equivalents (MMEs).30 A
daily MME per prescription was obtained using a product of daily dose per prescription and the MME
conversion factor for each opioid. The sum of the daily MME per prescription was determined in each
pregnancy trimester to obtain a cumulative MME per day for every patient. Median cumulative MME
per day was identified in each trimester and used as an empirical cutoff to dichotomize exposed
mothers into 2 groups: high and low exposure.
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Second, we examined associations between study outcomes and the 4 most commonly used
opioid drugs: hydrocodone, oxycodone, codeine, and tramadol.11 Women with 2 or more opioids
dispensed during pregnancy were excluded from this sensitivity analysis.
Third, to reveal the risk of individual prescription opioids associated with specific malformations
and dose responses, we further categorized the study outcomes and identified the diagnosed
indications that occurred with high incidence rates. We examined the association of these specific
outcomes with individual opioid drugs.
All analyses were conducted using SAS, version 9.4 (SAS Inc). The level at which statistical
significance was set was P ⱕ .05.

Results
Of 13 684 live births from January 1, 2008, to December 31, 2016, 10 768 mothers were enrolled in
the Rhode Island Medicaid program. The final study cohort included 12 424 infants, consisting of
11 533 (92.8%) born to unexposed mothers and 891 (7.2%) born to mothers dispensed at least 1
prescription opioid during pregnancy (eFigure in the Supplement).
Of the exposed infants, 433 (48.6%) were exposed to prescription opioids in trimester 1, 306
(34.3%) in trimester 2, 306 (34.3%) in trimester 3, and 42 (4.7%) in all 3 trimesters. Before the
propensity score method was applied (Table 1), exposed mothers in trimester 1, 2, or 3 were older;
had higher prevalence of substance use, chronic diseases, mental disorders, and pain conditions; and
were dispensed more concomitant medications at baseline and during pregnancy. After propensity
score stratifying and weighting, balance was achieved among all confounding factors, indicated by

Table 1. Selected Demographic and Clinical Characteristics of the Study Populationa
Trimester 1

Trimester 2

Characteristic

Exposed
Unexposed during
[Reference] trimester 1
(n = 11 533) (n = 433)

Exposed
Standardized difference during
Before PS After PS
trimester 2
adjustment adjustment (N = 306)

Age, mean (SD), y

25.7 (6.5)

0.37b

0.02

b

28 (6.5)

Trimester 3

Before PS After PS
adjustment adjustment

Exposed
during
trimester 3
(N = 306)

27 (6.2)

0.21b

−0.03

0.01

38 (12.4)

0.09

Standardized difference

Standardized difference
Before PS
adjustment

After PS
adjustment

27.9 (5.9)

0.35b

0.02

0.01

39 (12.7)

0.10

−0.01

Obesity, No. (%)

1104 (9.6)

65 (15.0)

0.17

Multiple births, No. (%)

298 (2.6)

18 (4.2)

0.09b

0.01

12 (3.9)

0.08

0

8 (2.6)

0

0

Tobacco use, No. (%)

1325 (11.5) 114 (26.3)

0.39b

0

76 (24.8)

0.35b

−0.02

85 (27.8)

0.42b

−0.01

199 (1.7)

12 (2.8)

0.07b

−0.03

9 (2.9)

0.08

22 (5.1)

b

Alcohol use, No. (%)
Other substance abuse, No. (%)

c

200 (1.7)

0

13 (4.2)

0.15b

−0.01

b

0.19

0.02

16 (5.2)

0.19

0.01

20 (6.5)

0.24b

0.01

Lower back pain, No. (%)

2478 (21.5) 229 (52.9)

0.69b

−0.02

139 (45.4)

0.52b

0.03

132 (43.1)

0.48b

0

Headache, No. (%)

1927 (16.7) 134 (30.9)

0.34b

−0.02

85 (27.8)

0.27b

−0.02

94 (30.7)

0.33b

0

Chronic pelvic pain, No. (%)

1765 (15.3) 112 (25.9)

0.26a

−0.02

69 (22.5)

0.19b

−0.01

73 (23.9)

0.22b

−0.01

Fibromyalgia, No. (%)

204 (1.8)

37 (8.5)

0.31b

0

27 (8.8)

0.32b

0

23 (7.5)

0.28b

−0.02

Diabetes, No. (%)

295 (2.6)

19 (4.4)

0.10b

0

9 (2.9)

0.02

−0.01

11 (3.6)

0.06

−0.01

Hypertension, No. (%)

362 (3.1)

28 (6.5)

0.16b

−0.01

21 (6.9)

0.17b

−0.02

14 (4.6)

0.07

−0.01

Depression, No. (%)

2379 (20.6) 150 (34.6)

0.32b

−0.01

104 (34)

0.30b

−0.03

104 (34)

0.30b

−0.04

Anxiety, No. (%)

1906 (16.5) 141 (32.6)

0.38

b

b

Bipolar disorder, No. (%)

417 (3.6)

36 (8.3)

ADHD, No. (%)

312 (2.7)

34 (7.9)

Menstrual disorders, No. (%)

−0.02

93 (30.4)

0.33

−0.01

91 (29.7)

0.32b

−0.03

0.20b

0

15 (4.9)

0.06

−0.02

25 (8.2)

0.19b

0

0.23b

0

18 (5.9)

0.16b

−0.01

16 (5.2)

0.13b

−0.02

3295 (28.6) 164 (37.9)

0.20b

−0.01

113 (36.9)

0.18b

−0.02

106 (34.6)

0.13b

−0.03

914 (7.9)

0.38b

−0.02

66 (21.6)

0.38b

−0.03

63 (20.6)

0.35b

−0.04

Use in baseline or trimester 1,
No. (%)
Antidepressants

91 (21)

b

b

Antipsychotics

124 (1.1)

15 (3.5)

0.16

−0.03

9 (2.9)

0.13

0.01

10 (3.3)

0.15b

0.01

Benzodiazepines

459 (4)

72 (16.6)

0.43b

−0.01

49 (16)

0.41b

0

44 (14.4)

0.38b

−0.02

Anticonvulsants

206 (1.8)

44 (10.2)

0.36b

0

21 (6.9)

0.25b

−0.01

20 (6.5)

0.24b

0

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; PS, propensity score.

b

Statistically significant at P < .05.

a

c

Included cocaine or marijuana use.

Characteristics with fewer than 11 occurrences were not reported.
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the weighted standardized difference less than 10% between 2 comparison groups in the 3
trimesters (Table 1).
Crude rates of outcome events and aRRs are presented in Table 2. Overall major birth defects
occurred at a similar rate among exposed compared with unexposed women (aRR, 1.40; 95% CI,
0.84-2.34). When stratifying major birth defects by organ systems, similar event rates in comparison
groups persisted. However, overall minor birth defects were significantly different in patients with
opioid exposure in trimester 3 vs opioid nonexposure (aRR, 1.26; 95% CI, 1.04-1.53). After examining
minor outcomes in 10 specific organ systems, a significantly increased risk of minor birth defects in
the musculoskeletal system was observed in mothers with opioid exposure in trimester 2 (aRR, 1.50;
95% CI, 1.10-2.03) and trimester 3 (aRR, 1.65; 95% CI, 1.23-2.22).
Table 3 presents the results of the dose-response effects examined using categorized
cumulative MME stratified by high or low exposure by the median in each trimester. The median
cumulative MME for trimester 1 was 30 mg/d; trimester 2, 37.5 mg/d; and trimester 3, 42.25 mg/d.
Baseline characteristics comparing high or low exposure with no exposure in the 3 trimesters are
presented in eTable 2 in the Supplement. High-dose opioid exposure and overall minor birth defects
showed significant dose responses in trimester 3 (aRR, 1.34; 95% CI, 1.03-1.73). Similar patterns were

Table 2. Crude Event Rates and Adjusted RR of Major and Minor Congenital Malformationsa
Crude event rates, No. (%)
Opioid exposure window

Outcome

Unexposed

Exposed

Adjusted RR (95% CI)b

Trimester 1: unexposed (n = 11 533)
vs exposed (n = 433)

Overall major birth defects

433 (3.8)

17 (3.9)

1.40 (0.84-2.34)

Trimester 2: unexposed (n = 11 533)
vs exposed (n = 306)

Overall minor birth defects

2464 (21.4)

77 (25.2)

1.11 (0.91-1.37)

Minor birth defects in the
musculoskeletal system

984 (8.5)

40 (13.1)

1.50 (1.10-2.03)

Trimester 3: unexposed (n = 11 533)
vs exposed (n = 306)

Overall minor birth defects

2464 (21.4)

85 (27.8)

1.26 (1.04-1.53)

Minor birth defects in the
musculoskeletal system

984 (8.5)

44 (14.4)

1.65 (1.23-2.22)

Abbreviation: RR, relative risk.
a

For each birth defect category, only significant results are presented.

b

Covariates adjusted for in the propensity score model included age; obesity; multiple
births; tobacco use; alcohol use; other substance abuse; lower back pain; headache;

chronic pelvic pain; fibromyalgia; history of diabetes, hypertension, depression,
anxiety, bipolar disorder, attention-deficit/hyperactivity disorder, and menstrual
disorders; and use of comedications during the baseline or exposure trimester,
including antidepressants, antipsychotics, benzodiazepines, and anticonvulsants.

Table 3. Adjusted RR of Major or Minor Congenital Malformations Associated With High or Low MME Prescription Opioid Exposurea
Event rates, No. (%)
Exposure window

Exposure

Outcome

Unexposed

Exposed

Adjusted RR (95% CI)b

Trimester 1

Cumulative MME ≥30 (n = 252)
vs unexposed (n = 11 533)

Overall major birth defects

433 (3.75)

11 (4.37)

1.53 (0.81-2.88)

Cumulative MME <30 (n = 181)
vs unexposed (n = 11 533)

Overall major birth defects

433 (3.75)

NA

1.09 (0.45-2.63)

Cumulative MME ≥37.5 (n = 171)
vs unexposed (n = 11 533)

Overall minor birth defects

2464 (21.36)

46 (26.90)

1.22 (0.94-1.57)

Minor birth defects in
musculoskeletal system

984 (8.53)

26 (15.20)

1.74 (1.20-2.53)

Cumulative MME <37.5 (n = 135)
vs unexposed (n = 11 533)

Overall minor birth defects

2464 (21.36)

31 (22.96)

1.02 (0.74-1.40)

Minor birth defects in
musculoskeletal system

984 (8.53)

14 (10.37)

1.16 (0.70-1.92)

Cumulative MME ≥42.25 (n = 153)
vs unexposed (n = 11 533)

Overall minor birth defects

2464 (21.36)

45 (29.41)

1.34 (1.03-1.73)

Minor birth defects in
musculoskeletal system

984 (8.53)

26 (16.99)

2.00 (1.38-2.91)

Cumulative MME <42.25 (n = 153)
vs unexposed (n = 11 533)

Overall minor birth defects

2464 (21.36)

40 (26.14)

1.18 (0.89-1.56)

Minor birth defects in
musculoskeletal system

984 (8.53)

18 (11.76)

1.36 (0.87-2.13)

Trimester 2

Trimester 3

Abbreviations: MME, morphine milligram equivalent; NA, not available; RR, relative risk.
a

The frequencies and percentages of outcome events are not presented if the numbers
are lower than 10.

b

Covariates adjusted for in the propensity score model included age; obesity; multiple
births; tobacco use; alcohol use; other substance abuse; lower back pain; headache;

chronic pelvic pain; fibromyalgia; history of diabetes, hypertension, depression,
anxiety, bipolar disorder, attention-deficit/hyperactivity disorder, and menstrual
disorders; and use of comedications during the baseline or exposure trimester,
including antidepressants, antipsychotics, benzodiazepines, and anticonvulsants.
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observed for minor congenital anomalies of the musculoskeletal system, which were related to
higher opioid doses in trimester 2 (aRR, 1.74; 95% CI, 1.20-2.53) and trimester 3 (aRR, 2.00; 95% CI,
1.38-2.91).
Maternal exposure to hydrocodone or codeine in trimester 2 was linked to higher risks of minor
birth defects in the musculoskeletal system (hydrocodone: aRR, 1.62; 95% CI, 1.01-2.59; codeine:
aRR, 2.24; 95% CI, 1.27-3.05). In trimester 3, codeine use was associated with overall minor birth
defects (aRR, 1.45; 95% CI, 1.04-2.00) and oxycodone use was associated with minor birth defects in
the musculoskeletal system (aRR, 1.77; 95% CI, 1.14-2.76) (Table 4).
Three minor anomalies in the musculoskeletal system that occurred in high frequencies and
were associated with opioid exposure in trimester 2 or 3 were plagiocephaly, polydactyly, and other
specified congenital deformities of the hip. Of those exposed to prescription opioids in trimester 2 or
3, a total of 45 infants were diagnosed with these 3 anomalies and 30 of these infants (66.7%) had
plagiocephaly. Adjusted results showed that a higher risk of these musculoskeletal anomalies was
linked to a high-dose maternal opioid exposure in trimesters 2 and 3. Hydrocodone use in trimester 2
(aRR, 3.01; 95% CI, 1.80-5.03) and oxycodone use in trimester 3 (aRR, 2.43; 95% CI, 1.37-4.02) were
associated with these 3 anomalies (Table 5).

Table 4. Significant Adjusted RR of Major or Minor Congenital Malformations Associated With Exposure
to Specific Opioids
Event rate, No. (%)

Abbreviation: RR, relative risk.

Outcome

Unexposed

Exposed

Adjusted RR (95% CI)a

Hydrocodone

Minor birth defects in the
musculoskeletal system

984 (8.53)

16 (13.22)

1.62 (1.01-2.59)

Codeine

Minor birth defects in the
musculoskeletal system

984 (8.53)

11 (16.42)

2.24 (1.27-3.05)

Opioid drug
Trimester 2

Trimester 3
Codeine

Overall minor birth defects

2464 (21.36)

26 (30)

1.45 (1.04-2.00)

Oxycodone

Minor birth defects in the
musculoskeletal system

984 (8.53)

18 (15.38)

1.77 (1.14-2.76)

a

Covariates adjusted for in the propensity score
model included age; obesity; multiple births; tobacco
use; alcohol use; other substance abuse; lower back
pain; headache; chronic pelvic pain; fibromyalgia;
history of diabetes, hypertension, depression,
anxiety, bipolar disorder, attention-deficit/
hyperactivity disorder, and menstrual disorders; and
use of comedications during the baseline or exposure
trimester, including antidepressants, antipsychotics,
benzodiazepines, and anticonvulsants.

Table 5. Adjusted RR of Specific Minor Congenital Malformations in the Musculoskeletal System Associated
With MME Dose and Individual Prescription Opioid Exposurea
Event rate, No. (%)
Exposure

Unexposed

Exposed

Adjusted RR (95%
CI)b

Trimester 2

Cumulative MME≥37.5 (n = 171) vs
unexposed (n = 11 533)

578 (5.01)

19 (11.11)

2.49 (1.58-3.94)

Trimester 3

Cumulative MME≥42.25 (n = 171) vs
unexposed (n = 11 533)

578 (5.01)

16 (10.46)

2.56 (1.57-4.16)

Trimester 2

Hydrocodone (n = 121) vs unexposed
(n = 11 533)

578 (5.01)

14 (11.57)

3.01 (1.80-5.03)

Trimester 3

Oxycodone (n = 117) vs unexposed
(n = 11 533)

578 (5.01)

13 (11.11)

2.43 (1.37-4.02)

Exposure window
MME dose

Specific opioids

Abbreviations: MME, morphine milligram equivalent; RR, relative risk.
a

Specific minor congenital malformations in musculoskeletal system included plagiocephaly or congenital musculoskeletal
deformities of the skull, face, and jaw; other specified congenital deformities of the hip; and polydactyly of fingers.

b

Covariates adjusted for in the propensity score model included age, obesity, multiple births, tobacco use, alcohol use,
other substance abuse, lower back pain, headache, chronic pelvic pain, and fibromyalgia; history of diabetes,
hypertension, depression, anxiety, bipolar disorder, attention-deficit/hyperactivity disorder, and menstrual disorder; and
use of comedications during the baseline or exposure trimester, including antidepressants, antipsychotics,
benzodiazepines, and anticonvulsants.
JAMA Network Open. 2021;4(4):e215708. doi:10.1001/jamanetworkopen.2021.5708 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a University of Rhode Island User on 05/05/2021

April 13, 2021

6/12

JAMA Network Open | Pharmacy and Clinical Pharmacology

Gestational Opioid Exposure and Risk of Congenital Malformations

Discussion
This study found that opioid dispensing in the first trimester was associated with no excess risk of
major birth defects. Opioid exposure in the third trimester was associated with a 1.26-fold higher risk
of overall minor congenital malformations compared with no exposure. After classifying by organ
systems, prenatal opioid exposure in the second trimester was associated with a 1.50-fold higher risk
and in the third trimester was associated with a 1.65-fold higher risk of minor malformations in the
musculoskeletal system. The risk of minor birth defects overall or in the musculoskeletal system was
higher with greater exposure in the third trimester. Such a dose-exposure effect would be expected
of a teratogen, an agent that causes fetal malformation.
The prevalence of major congenital malformation is approximately 3% among live births in the
US31; the reported incidence of minor congenital anomalies in newborns is more frequent and ranges
from 14.7% to 47.7%, depending on population, defect types, and method of ascertainment.32-38
Infants with minor anomalies, mostly consisting of structural changes that pose less serious
morbidity and disability, have a greater risk of more serious major malformations, developmental
problems, or mental disorders.32,34,39-41 To our knowledge, no previous studies have examined the
risk of minor anomalies in children with prenatal opioid exposure.
Consistent with teratology theory,42 our study suggests that minor congenital malformations in
the musculoskeletal system are significantly associated with maternal opioid dispensing during the
second or third trimester in a dose-dependent manner. Three anomalies that were
disproportionately high in infants with prenatal opioid exposure in the second or third trimester were
plagiocephaly, polydactyly, and other specified congenital deformities of the hip. The
musculoskeletal system appears to be the third most common organ system (approximately 16%)
involved in congenital malformations, preceded by the circulatory system (26%) and genitourinary
system (21%).43-45 Infants with deformational plagiocephaly exhibited a higher rate of
developmental delay and cognitive dysfunction.46-48 One study reported the high incidence of
torticollis in infants with neonatal abstinence syndrome.49 Opioid use in pregnancy has been
associated with dislocated hip and musculoskeletal defects and polydactyly.5,50,51 In our study, a high
risk of plagiocephaly, along with hip deformities and polydactyly, was associated with higher doses
of opioid use in the second and third trimesters.
Previous studies have reported an association between gestational opioid analgesia and major
congenital malformations. Broussard et al8 reported that opioids were associated with various
congenital heart malformations, spina bifida, and gastroschisis. Källén and colleagues52,53 found
associations of severe congenital malformations, cardiovascular defects, and clubfoot with opioids,
including tramadol. Other studies suggested that codeine is related to a higher risk of overall birth
defects, spina bifida, and cardiovascular defects.51,54-56 A recent study by Bateman et al6 suggested
no association between prenatal opioid exposure in the first trimester and major congenital
malformations. In our study, major congenital malformations were not associated with prenatal
opioid use in the first trimester. Hydrocodone, oxycodone, and codeine use in trimester 2 or 3 were
related to a higher risk of malformations in the musculoskeletal system. Although these findings are
based on a small number of outcome events, hydrocodone, oxycodone, tramadol, and codeine in
general showed higher risks of congenital malformations and toxic effects in the fetus.
Mechanisms causing opioid teratogenicity are important but frequently unknown. Earlier
animal studies suggested that endogenous opioid growth factor interacting with the ζ opioid
receptor reduces DNA synthesis in the organs’ cells, thus affecting organ development in the
fetus.57,58 Morphine-induced birth defects in the central nervous system could result from
neuroblast apoptosis that relates to upregulated Bax to Bcl-2 ratio and caspase-3 activity in the early
stage of fetal development.59 An animal study observed the developmental toxic effects of prenatal
codeine use at a dose 11-fold higher than the maximum human therapeutic dose.60 More
mechanism-oriented studies need to be conducted to examine the role of commonly prescribed
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opioids as growth regulators in organs and tissues and the association between gestational opioid
exposure and congenital malformations.
The association between iatrogenic opioid exposure and birth defects, whether major or minor,
increases the importance of the reduction of prescribed opioids during pregnancy. The American
College of Obstetricians and Gynecologists specifically recommends that opioid analgesia should be
used only in cases of severe pain.3 However, comprehensive educational initiatives are necessary to
remind obstetricians, nurse midwives, and any other clinician who cares for women in pregnancy,
including in an emergency setting, that nonopioid modalities for pain management should be firstline therapy during pregnancy. Only in the setting of a failed first-line nonopioid regimen and
persistent pain does the benefit of maternal opioid exposure clearly outweigh the risk of potential
fetal congenital malformation. Furthermore, it appears advisable to limit the dose of treatment when
opioids are needed.

Limitations
This study has several limitations. First, outpatient pharmacy claims data indicated that opioid
medication was dispensed to the patient but may not reflect what was taken. Inpatient or illicit opioid
use was not captured within these data. Prescription opioids may also be obtained from relatives,
friends, and acquaintances. Prescription sharing for opioids ranges from 5% to 51.9%.61 Second,
some uncertainty is present in estimating the ultrasonographically confirmed gestational age and the
gestational weeks for opioid use in different trimesters. However, most of the first trimesters should
be largely represented, thereby supporting the estimated association in the first trimester between
opioid use and major malformations, but minor malformations could be associated with opioid use
later in pregnancy. Third, only live births were included in this study; stillbirths, miscarriages, and
pregnancy terminations were not examined, Furthermore, all minor birth defects were assessed
using infants’ Medicaid claims; maternal Medicaid records were not used. Fourth, although many
studies examining this association are available, a definitive conclusion that opioid exposure is
responsible for congenital malformations is not possible because other studies, like ours, are
associative in design. Unmeasured confounding factors, including race/ethnicity, lifestyle, severity of
pain, environmental exposures, folic acid supplementation before or during pregnancy, and other
comorbidities, could not be considered. Confounding by indication could be an issue for the study
comparing exposed with unexposed pregnancies. However, we adjusted for many pain conditions in
the analyses. Fifth, statistical power was insufficient for some analyses because of the rare frequency
of exposure and outcomes. Thus we were not able to assess the association between a specific opioid
or MME dose and a specific type of major birth defect. In addition, this study comprised mothers and
infants of lower socioeconomic status insured by the state Medicaid program. This limited population
may affect the generalizability of the study results.

Conclusions
Our findings suggest that prenatal exposure to prescription opioids in the first trimester is not
associated with major birth defects. In the second and third trimesters, it is associated with a higher
risk of minor congenital malformations in a dose-dependent manner. Weighing risks and benefits
before prescribing opioid drugs to pregnant women or women of childbearing age (in case of
unintended pregnancy) could help reduce harm to the fetus. Further investigation in observational
studies with larger study cohorts and basic science research with animal models are warranted to
provide further support.
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